EPO Board of Appeal finds Broad Institute’s CRISPR patent to lack valid priority claim and upholds revocation of patent (T 0844/18)

17/01/20

This week’s hearing at the EPO concerning Broad Institute’s CRISPR/Cas9 patent was arguably one of the most high-profile appeals recently...